Another ongoing clinical trial of anti-PSMA CAR T therapy aims to be combined with PD-1 blockade in treating mCRPC (NCT04768608), opening new treatment paradigms for CAR T cell therapy as an alternate treatment option for PCa (Table 1). The gene discussed is PDCD1; the disease is posterior cortical atrophy.